Thoughts on Ide-cel Data Presentation at ASH 2020; FDA Unlikely to Hold an Ide-cel Advisory Committee Meeting; Summary of bluebird at Jefferies Cell Therapy Summit
On Tuesday, October 6, bluebird bio at the Jefferies Cell Therapy Virtual Summit (press release) highlighted upcoming clinical results for ide-cel at ASH 2020. Of note, bluebird discussed ide-cel’s projected approval timeline and the possibility of an FDA Advisory Committee Meeting. Furthermore, management outlined their position on ide-cel combinations with gamma-secretase inhibitors. Below, Celltelligence provides thoughts on ide-cel’s anticipated clinical update and bluebird’s possible messaging strategy for autologous CAR-Ts vs allogeneics.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.